INV-202 Induces Weight Loss and Reduces Airway Hyperreactivity in Mouse Model of Obese Asthma
Montreal, Canada– May 22, 2023 – Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced positive results from a proof-of-concept study of INV-202 in a mouse model of obese asthma at the American Thoracic Society (ATS) International Conference taking place from May 19-24, 2023, in Washington, D.C.
In an oral presentation, Carolyn R. Morris, PhD, Faculty Scientist, University of Vermont, Burlington, VT will discuss results from a proof-of-concept study designed to test the efficacy of INV-202 in a mouse model of obese asthma for direct effects on the airway and weight loss. INV-202, Inversago’s lead drug candidate, is a potential first-in-class, peripheral CB1r blocker, being developed to treat metabolic disorder complications.
“People with asthma and obesity have worse quality of life, worse asthma control and more exacerbations than people with asthma without obesity, and this is associated with adipose tissue inflammation and metabolic dysfunction,” said Anne Dixon, M.D., Professor of Pulmonology at Larner College of Medicine, at the University of Vermont, in whose lab the study was conducted.
“INV-202 is being developed for the treatment of metabolic disorder complications, and this preclinical data demonstrates its potential to also address the large unmet need in asthma complicated by obesity,” added Glenn Crater MD, Chief Medical Officer of Inversago.
Presentation Details:
Abstract Title: Cannabinoid Receptor 1 Inverse Agonist, INV-202, Induces Weight Loss and Reduces Airway Hyperreactivity in a Mouse Model of Obese Asthma
Presenter: Carolyn R. Morris, PhD, Faculty Scientist, University of Vermont, Burlington, VT
Session: B15 – ASTHMA: HOT OFF THE PRESS FROM THE BENCH TO THE CLINIC
Date and Time: Monday, May 22, 2023, 9:00 – 11:00 AM ET
About INV-202
INV-202 is a small molecule CB1r blocker being developed for the potential treatment of a range of cardiometabolic conditions, including diabetic kidney disease. It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. The therapeutic effects of a peripheral CB1r blockade in a range of cardiometabolic and fibrotic diseases are well-documented, paving the way for potential treatment of a large number of patients with current unmet needs. INV-202 is being evaluated in a Phase 2 study for patients with diabetic kidney disease with results expected in mid 2024.
About Inversago
Based in Montreal Canada, Inversago Pharma, is a privately owned, clinical stage company, and leader in the development of peripherally acting CB1r blocker therapies designed to help patients with complications associated with metabolic and fibrotic diseases. Inversago aims to provide new treatment options that improve the lives of patients affected by diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive fibrosis-interstitial lung disease (PF-ILD), including idiopathic pulmonary fibrosis (IPF) and other conditions.
Contact
Glenn S. Vraniak
Chief Financial Officer
Inversago Pharma Inc.
info@inversago.com
Media and Investors
Argot Partners
inversago@argotpartners.com
